Addressing Knowledge Gaps in Management of Tumor Lysis Syndrome

Recently, i3 Health provided a continuing medical education/nursing continuing professional development/continuing pharmacy education (CME/NCPD/CPE)–approved activity, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies, during which clinicians' knowledge gaps were challenged and knowledge gains were achieved. Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor c...

Elacestrant Approved for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer

The FDA has approved elacestrant (Orserdu™, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer with disease progression subsequent to at least one line of endocrine therapy. Additionally, the FDA approved the Guardant360 CDx assay, a companion diagnostic test, to identify breast cancer patients eligible for treatme...

Pirtobrutinib Granted Accelerated Approval for Mantle Cell Lymphoma

The FDA has granted accelerated approval to pirtobrutinib (Jaypirca™, Eli Lilly and Company) for patients with relapsed or refractory mantle cell lymphoma (MCL) following a minimum of two lines of systemic therapy that included a Bruton tyrosine kinase inhibitor (BTKi). "Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi, inhibits both wildtype and C481-mutant BTK with equal low nanomolar (nM) potency, and has favorable oral pharmacology that enables continuous BTK inhibition thro...

Pembrolizumab Approved for Adjuvant Treatment of Non–Small Cell Lung Cancer

The FDA has approved pembrolizumab (Keytruda®, Merck) for adjuvant treatment of stage IB, II, or IIIA non–small cell lung cancer (NSCLC), following resection and platinum-based chemotherapy. "Although adjuvant chemotherapy improves overall survival in completely resected NSCLC, the absolute 5-year survival benefit is moderate compared with observation alone," wrote Mary O'Brien, MD, Head of Royal Marsden Hospital's Lung Unit, and colleagues, in their published results of the KEYNOTE-091 trial (N...

Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD

Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss her presentation regarding the relevance of urine studies in myeloma patients undergoing transplantation. This podcast episode was recorded live by O...

Overcoming Knowledge Gaps in Thyroid Cancer Management

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding management and novel treatment options for differentiated and anaplastic thyroid cancer. Thyroid cancer is one of the most prevalent cancers in the United States. The American Cancer Society estimates 43,720 new cases and 2,120 deaths from the disease in the United States over the course of 2023. Thyroid cancer is typically more aggressive in men than in women and becomes increas...

GLAONS Survey of Oncology Nurses Reveals Knowledge Gap Regarding Novel Treatment Options

In September 2022, i3 Health conducted a survey of 157 oncology nurses at the Greater Los Angeles Oncology Nursing Society (GLAONS) 6th Annual Oncology Care Summit to assess nurses' familiarity with and desire to understand novel oncology treatment options, including chimeric antigen receptor (CAR) T-cell therapies, cyclin-dependent kinase (CDK)4/6 inhibitors, immune checkpoint inhibitors, poly-ADP ribose polymerase (PARP) inhibitors, and antibody-drug conjugates. CAR T-cell therapy has been sho...

Zanubrutinib Approved for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The FDA has approved zanubrutinib (Brukinsa®, BeiGene USA, Inc.) for treatment of chronic lymphocytic leukemia (CLL) and its tissue counterpart, small lymphocytic lymphoma (SLL). "Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed CLL and SLL," wrote Constantine Tam, MD, the Director of Hematology at St. Vincent's Hospital in Melbourne, Australia, and colleagues, in their abstract of the SEQUOIA trial (NCT03336333), one of the studies on which...

Tucatinib Plus Trastuzumab Approved for Colorectal Cancer

The FDA has granted accelerated approval to tucatinib (Tukysa®, Seagen, Inc.) with trastuzumab for rat sarcoma (RAS) wild-type human epidermal growth factor receptor 2 (HER2)–positive unresectable or metastatic colorectal cancer (CRC) that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. "Patients with chemotherapy-refractory HER2-positive metastatic colorectal cancer receive limited clinical benefit with currently available therapies," said John Stric...

FDA Oncology Approvals in 2022: Timeline of Novel Treatment Options

The past year has been filled with new and exciting improvements and novel treatment options in the field of oncology and hematology. The FDA has granted approval and accelerated approval to many new drugs and drug combinations, including the very first approval for patients with HER2-mutant non–small cell lung cancer, trastuzumab deruxtecan. This is a great time to reflect on the current treatment landscape and ponder what 2023 could have in store for future approvals and emerging treatment opt...

GLAONS Survey of Oncology Nurses Reveals Knowledge Gap Regarding Genetic Evaluation and LGBTQIA+ Cancer Care

In September 2022, i3 Health conducted a survey of 157 oncology nurses at the Greater Los Angeles Oncology Nursing Society (GLAONS) 6th Annual Oncology Care Summit to assess nurses' familiarity with and desire to understand genetic evaluation and counseling and LGBTQIA+ cancer care. Through genetic evaluation and counseling care, patients can better understand their genome and how their DNA might be able to warn them, and even their family, about their risks of developing certain cancers and dis...

Uncovering Racial Disparities Experienced in Breast Cancer Patients With Yara Abdou, MD

At the recent San Antonio Breast Cancer Symposium (SABCS), Yara Abdou, MD, Assistant Professor of Hematology and Oncology and Medical Oncologist at The University of North Carolina School of Medicine, presented her team's research on the disparities that Black women with breast cancer experience. Afterwards, she spoke with Oncology Data Advisor to go into further detail on her findings, as well as to answer a few questions regarding future clinical trials and research to explore disparities Blac...

Additional Advances in Multiple Myeloma Research and Clinical Trials: With Sarah Holstein, MD, PhD

Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about wh...

Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD

Oncology Data Advisor™ · Highlights from the San Antonio Breast Cancer Symposium At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares the four abstracts which he believes will have the grea...

Nadofaragene Firadenovec-vncg Approved for Non–Muscle-Invasive Bladder Cancer

The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin®, Ferring Pharmaceuticals) for treatment of high-risk Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Nadofaragene firadenovec-vncg is a non-replicating adenoviral vector-based gene therapy that cannot multiply in human cells and the first gene therapy to be approved for high-risk NMIBC. "BCG is the most effective therapy for h...

Additional Advances in Multiple Myeloma Research and Clinical Trials With Sarah Holstein, MD, PhD

Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about what to look forward to from this year's ASH Annual Meeting. Oncology Data Advisor: Welcome to...

Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD

Oncology Data Advisor™ · Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS). Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. To...

Adagrasib Approved for KRAS G12C–Mutated Non–Small Cell Lung Cancer

The FDA has granted accelerated approval to adagrasib (Krazati™, Mirati Therapeutics, Inc.) for treatment of adult patients with kirsten rat sarcoma viral oncogene homologue (KRAS) G12C–mutated locally advanced or metastatic non­–small cell lung cancer (NSCLC). Patients should have received one prior line of systemic therapy. Adagrasib is a rat sarcoma virus (RAS) guanosine triphosphatase (GTPase) family inhibitor. "Adagrasib (MRTX849), a potent, orally available, small molecule covalent inhibit...

Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP

With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.  

Atezolizumab Approved for Alveolar Soft Part Sarcoma

The FDA has granted approval to atezolizumab (Tecentriq®, Genentech, Inc.) for treatment of unresectable or metastatic alveolar soft part sarcoma (ASPS) in patients two years of age and older. Atezolizumab is an immune checkpoint inhibitor targeting programmed cell death ligand 1 (PD-L1). Safety and efficacy were measured in a phase 2, open-label, single-arm study (NCT03141684) which enrolled 49 patients with histologically or cytologically confirmed ASPS incurable by surgery and an Eastern Coop...

Copyright © 2022 Oncology Data Advisor. All rights reserved.